Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

NCT02475213 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Head and Neck Cancer
Non Small Cell Lung Cancer
Urothelial Carcinoma

Interventions

BIOLOGICAL: Enoblituzumab Schedule 1
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Enoblituzumab Schedule 2
BIOLOGICAL: retifanlimab

Sponsor

MacroGenics